ArticleClinical and vaccine immunology : CVI2008
Vaccination against Pseudomonas aeruginosa pneumonia in immunocompromised mice.
Article in Clinical and vaccine immunology : CVI, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- Review
- The promoting role of aluminum oxide nanoparticles in enhancingOpen veterinary journal · 2025Article
- To bead or not to bead: A review ofFrontiers in physiology · 2023Review
- Nanotoxoid vaccination protects against opportunistic bacterial infections arising from immunodeficiency.Science advances · 2022Article
- A live auxotrophic vaccine confers mucosal immunity and protection against lethal pneumonia caused by Pseudomonas aeruginosa.PLoS pathogens · 2020Article
- Hemorrhage Attenuates Neutrophil Recruitment in Response to Secondary Respiratory Infection by Pseudomonas Aeruginosa.Shock (Augusta, Ga.) · 2019Article
- Genome-Based Approach Delivers Vaccine Candidates AgainstFrontiers in immunology · 2018Article
- Activated βAmerican journal of respiratory cell and molecular biology · 2017Article
- Adjuvant role of Pseudomonas flagellin for Acinetobacter baumannii biofilm associated protein.World journal of methodology · 2016Article
- Four-component Staphylococcus aureus vaccine 4C-staph enhances Fcγ receptor expression in neutrophils and monocytes and mitigates S. aureus infection in neutropenic mice.Infection and immunity · 2015Article
- Development and evaluation of murine lung-specific disease models for Pseudomonas aeruginosa applicable to therapeutic testing.Pathogens and disease · 2015Article
- Vaccine protection of leukopenic mice against Staphylococcus aureus bloodstream infection.Infection and immunity · 2014Article
- Vaccines for Pseudomonas aeruginosa: a long and winding road.Expert review of vaccines · 2014Review
- Bacterial infections in Myd88-deficient mice.Comparative medicine · 2014Article
- Perturbation of pulmonary immune functions by carbon nanotubes and susceptibility to microbial infection.Journal of microbiology (Seoul, Korea) · 2014Review
- Helical carbon nanotubes enhance the early immune response and inhibit macrophage-mediated phagocytosis of Pseudomonas aeruginosa.PloS one · 2013Article
- Why is Pseudomonas aeruginosa a pathogen?F1000 biology reports · 2010Article
- Evaluation of flagella and flagellin of Pseudomonas aeruginosa as vaccines.Infection and immunity · 2010Article
- Inescapable need for neutrophils as mediators of cellular innate immunity to acute Pseudomonas aeruginosa pneumonia.Infection and immunity · 2009Article
- IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa.Journal of immunology (Baltimore, Md. : 1950) · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Immunocompromised patients are highly susceptible to infection with Pseudomonas aeruginosa. Our laboratory previously showed that intranasal administration of an attenuated Salmonella strain expressing the P. aeruginosa lipopolysaccharide O antigen was effective in clearing bacteria and preventing mortality in wild-type mice after intranasal challenge. We were interested in investigating the efficacy of this vaccine strategy in immunocompromised mice. Mice rendered leukopenic or neutropenic by intraperitoneal treatment with cyclophosphamide (Cy) or RB6-8C5 antibody, respectively, were more susceptible to P. aeruginosa pneumonia than their nontreated counterparts, demonstrating 50% lethal doses several logs lower than that in wild-type mice. This hypersusceptiblity was also associated with bacterial dissemination to the liver and spleen and increased lung permeability in Cy mice. Vaccination of the mice prior to treatment resulted in better survival and lower bacterial loads compared to vector-immunized mice. Although the treatments had no effect on antibody titers, this level of protection was still lower than that seen in untreated vaccinated mice. Administration of antibodies directly to the site of infection at the time of bacterial delivery prolonged survival and lowered bacterial loads in the immunocompromised mice. These results demonstrate the importance of white blood cells while still suggesting a critical role for antibodies in protection against P. aeruginosa infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.